+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Matrix metalloproteinases and myocardial infarction



Matrix metalloproteinases and myocardial infarction



Canadian Journal of Cardiology 23(9): 727-733



Acute myocardial infarction (AMI) is currently one of the most important health problems in many Countries around the world. Following AMI, many cytokines and proteolytic enzymes are released. Among these, matrix metalloproteinases (MMPs) are important proteolytic enzymes that lead to degradation of the extracellular matrix and to changes in cardiomyocytes in both infarcted and noninfarcted myocardium. This process is known as cardiac remodelling. It has been demonstrated that more than one type of MMP is present in the circulation after cardiomyocyte injury. A number of studies have demonstrated the correlations between these MMP levels and the severity of a coronary lesion, the progression of left ventricular dimension and the survival rate following AMI in both animal and human Studies. MMPs have also been proposed as a possible novel prognostic indicator for myocardial infarction patients. Although the use Of MMP inhibitors to improve cardiac outcome in AMI patients has been investigated, discrepancies in the results from those studies indicate that further research is still needed to warrant their beneficial effects. In the present review article, the roles of MMPs as prognostic indicators, as well as the factors influencing MMP expression, are discussed. Current findings on the role of MMP inhibitors in cardiac remodelling and the prognosis after AMI in both animal models and clinical studies are also examined.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 016335857

Download citation: RISBibTeXText

PMID: 17622396

DOI: 10.1016/s0828-282x(07)70818-8


Related references

Differential release of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients following alcohol induced myocardial infarction. Circulation 104(17 Supplement): II 305, October 23, 2001

Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovascular Therapeutics 30(1): 31-41, 2012

Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. Journal of Surgical Research 172(1): 59-67, 2012

Matrix metalloproteinases activity in acute myocardial infarction patients Do their activity contributed to post-myocardial infarction dilation?. European Heart Journal 23(Abstract Supplement): 225, August-September, 2002

Time course of changes in matrix metalloproteinases after myocardial infarction in the rat. FASEB Journal 15(5): A1140, March 8, 2001

Matrix metalloproteinases: drug targets for myocardial infarction. Current Drug Targets 14(3): 276-286, 2013

Expression of matrix metalloproteinases in patients with acute myocardial infarction. Japanese Circulation Journal 65(2): 71-75, 2001

Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. Journal of Interventional Cardiology 17(1): 27-31, 2004

Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart 97(19): 1542-1546, 2011

Matrix metalloproteinases as markers of adverse remodeling after myocardial infarction. Journal of Cardiac Failure 12(1): 73-76, 2006

Inhibition of matrix metalloproteinases alters myocardial collagen turnover after infarction. Journal of Molecular & Cellular Cardiology 31(6): A123, June, 1999

Influence of matrix metalloproteinases on ventricular remodeling following myocardial infarction in the rats. Zhonghua Xinxueguanbing Zazhi 31(3): 223-225, March, 2003

Clinical significance of matrix metalloproteinases activity in acute myocardial infarction. European Cytokine Network 16(2): 152-160, 2005

Serum levels of matrix metalloproteinases 2 and 9 in patients with acute myocardial infarction. Folia Biologica 59(5): 181-187, 2014

Elevation of matrix metalloproteinases and interleukin-6 in the culprit coronary artery of myocardial infarction. European Journal of Clinical Investigation 38(3): 166-173, 2008